Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477882 | 0.82 | ADRB1 (0.36) | — | |
| SCHEMBL1182091 | 0.81 | NOS3 (0.35) | — | |
| SCHEMBL152217 | 0.81 | — | — | |
| SCHEMBL2490012 | 0.80 | BTK (0.31) | — | |
| SCHEMBL3044575 | 0.78 | CDK2 (0.32) | — | |
| SCHEMBL3559087 | 0.78 | SOS2 (0.33) | — | |
| SCHEMBL478257 | 0.74 | SMN1; SMN2 (0.36) | ALDH1A1 | |
| SCHEMBL4258665 | 0.73 | CD38 (0.38) | CYP3A4TSHRALDH1A1 | |
| SCHEMBL3764758 | 0.72 | — | — | |
| SCHEMBL14994712 | 0.72 | L3MBTL1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025068354-A1 | SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025068132-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025017045-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20100249084-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| EP-2132197-A2 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | Almirall, S.A. (ES) | 2009-12-16 | — | — | EP | disclosed |
| US-7625895-B2 | Diphenyl-dihydro-imidazopyridinones | Hoffmann-Le Roche Inc. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-2076512-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-07-08 | — | — | EP | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080255119-A1 | DIPHENYL-DIHYDRO-IMIDAZOPYRIDINONES | DOMINIQUE ROMYR | 2008-10-16 | — | — | US | disclosed |
| WO-2008116185-A2 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008044022-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249084-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA1, ADORA2A | CYP3A4 965/4885TSHR 457/4885ALDH1A1 381/4885 |
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | JAK1, MTOR, MOK | CYP3A4 1715/4885TSHR 1930/4885ALDH1A1 1714/4885 |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | SCD5, SCD, FADS2 | CYP3A4 201/4885TSHR 2299/4885ALDH1A1 398/4885 |
| US-11352330-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | CYP3A4 500/4885TSHR 1723/4885ALDH1A1 131/4885 |
| US-20080255119-A1 | DIPHENYL-DIHYDRO-IMIDAZOPYRIDINONES | TP53, MDM2, TP53BP1 | CYP3A4 3296/4885TSHR 1836/4885ALDH1A1 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.